RT Book, Section
A1 Gilligan, Timothy
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127648736
T1 Testicular Cancer
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127648736
RD 2024/04/18
AB Although  testis  cancer  is  rare  when  viewed  across  the  lifespan,  it  is  the  most  common  malignancy  in  men  aged  20–35  years.  Thanks  to  the  high  cure  rate  of  the  disease,  however,  it  represents  fewer  than  5%  of  cancer  deaths  during  those  ages.  In  2013,  there  were  about  7,920  new  cases  and  370  deaths  from  testicular  cancer.  Incidence  is  relatively  stable  while  mortality  has  been  in  decline.  The  declining  mortality  rate  is  attributed  to  the  development  of  curative  chemotherapy  for  advanced  disease,  improved  treatment  algorithms,  earlier  stage  at  presentation,  and  a  growing  proportion  of  seminomas  relative  to  nonseminomas.  The  U.S.  male  lifetime  risk  of  being  diagnosed  with  testis  cancer  is  between  3  and  4  in  1000.  Testis  cancer  is  exceedingly  rare  in  African  American  men,  whose  incidence  of  the  disease  is  one-fifth  that  of  white  Americans.